LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 10

Search options

  1. Article ; Online: A case of juvenile systemic sclerosis and congenital pulmonary airway malformation related mucinous adenocarcinoma of the lung: paraneoplastic syndrome or just a coincidence?

    Aliyeva, Ayten / Adrovic, Amra / Ocak, Süheyla / Batur, Şebnem / Yıldız, Mehmet / Haşlak, Fatih / Köker, Oya / Şahin, Sezgin / Barut, Kenan / Kasapçopur, Özgür

    The Turkish journal of pediatrics

    2022  Volume 64, Issue 2, Page(s) 394–399

    Abstract: Background: Juvenile systemic sclerosis (JSS) is an extremely rarely seen auto-immune disease characterized by the increased fibrosis of skin and internal organs. Congenital pulmonary airway malformation (CPAM) is a developmental disorder of the lung, ... ...

    Abstract Background: Juvenile systemic sclerosis (JSS) is an extremely rarely seen auto-immune disease characterized by the increased fibrosis of skin and internal organs. Congenital pulmonary airway malformation (CPAM) is a developmental disorder of the lung, characterized by atypical cell hyperplasia which creates the ground for lung adenocarcinoma. In general, CPAM is diagnosed in early childhood, due to recurrent respiratory symptoms including cough, hemoptysis and respiratory infections. Although rare, there are some sporadic asymptomatic cases of CPAM that have been reported. We present a case with a coincidental presence of two rare diseases: JSS and CPAM.
    Case: An adolescent female patient was admitted to hospital due to clinical signs of JSS. During the followup, the patient had been diagnosed with cystic adenoid malformation of the lung complicated by mucinous adenocarcinoma. The patient was previously healthy with an unremarkable history, including lack of respiratory symptoms. Left inferior lobectomy was performed. Considering the small size of malignant loci, the total resection of the tumor and absence of any sign for metastasis disease, adjuvant therapy was not scheduled. We haven`t found a pediatric case of CPAM associated adenocarcinoma of the lung presented by signs of JSS in the literature. In this case, the clinical signs of JSS possibly represent part of the paraneoplastic syndrome related to adenocarcinoma of the lung.
    Conclusions: Internal organ involvement, including respiratory system, should not be omitted even in asymptomatic patients with JSS. Auto-antibody negativity represents a clue for the possible underlying condition. Further studies with a higher number of patients would reveal more relevant data.
    MeSH term(s) Adenocarcinoma/complications ; Adenocarcinoma, Mucinous/complications ; Adenocarcinoma, Mucinous/diagnosis ; Adenocarcinoma, Mucinous/pathology ; Adolescent ; Child ; Child, Preschool ; Cystic Adenomatoid Malformation of Lung, Congenital/complications ; Cystic Adenomatoid Malformation of Lung, Congenital/diagnosis ; Cystic Adenomatoid Malformation of Lung, Congenital/pathology ; Female ; Humans ; Lung/pathology ; Lung Neoplasms/complications ; Lung Neoplasms/diagnosis ; Paraneoplastic Syndromes/diagnosis ; Paraneoplastic Syndromes/etiology ; Scleroderma, Localized ; Scleroderma, Systemic/complications
    Language English
    Publishing date 2022-05-21
    Publishing country Turkey
    Document type Case Reports
    ZDB-ID 123487-0
    ISSN 2791-6421 ; 0041-4301
    ISSN (online) 2791-6421
    ISSN 0041-4301
    DOI 10.24953/turkjped.2020.2997
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: An overview of the relationship between juvenile idiopathic arthritis and potential environmental risk factors: Do early childhood habits or habitat play a role in the affair?

    Koker, Oya / Aliyeva, Ayten / Sahin, Sezgin / Adrovic, Amra / Yildiz, Mehmet / Haslak, Fatih / Gunalp, Aybuke / Barut, Kenan / Kasapcopur, Ozgur

    International journal of rheumatic diseases

    2022  Volume 25, Issue 12, Page(s) 1376–1385

    Abstract: Aim: The current study was undertaken to evaluate the influence of breastfeeding on the development and outcome measures of juvenile idiopathic arthritis (JIA). The second aim was to determine the consequences of particular sociodemographic and ... ...

    Abstract Aim: The current study was undertaken to evaluate the influence of breastfeeding on the development and outcome measures of juvenile idiopathic arthritis (JIA). The second aim was to determine the consequences of particular sociodemographic and sociocultural characteristics and nutritional behavior of early childhood on JIA.
    Methods: The study includes the patients diagnosed with JIA and regularly followed up at the Department of Pediatric Rheumatology in Istanbul University-Cerrahpasa. The comparison group consisted of healthy subjects and patients with juvenile systemic lupus erythematosus (jSLE). A face-to-face survey method was conducted with the parents of the participants between February 1, 2021, and September 1, 2021.
    Results: The mean age of the JIA cohort (n = 324) was 12.2 ± 4.7 years, with a female ratio of 64.8%. The breastfeeding rate differed from the control groups (253 healthy subjects and 88 patients with jSLE) but was higher with a value of 94.8%. There was no difference between the groups (P = .097, P = .064) or within the subgroups of JIA (P = .12) regarding breastfeeding duration. Cow's milk introduction time (P = .02, P = .0001), household pet-keeping (P = .001), income level (P = .0001), maternal literacy (P = 0.013) made a statistical difference vs the control groups.
    Conclusion: No relationship was established between the rate or duration of breastfeeding and the development or severity of JIA. The early introduction of cow's milk was found to be higher in the patient cohorts. The income level and maternal literacy appeared to be relevant with the high disability and damage scores, and frequent relapse rates. Secondhand smoking, higher in JIA, may prompt the basis of primary preventable strategies in JIA.
    MeSH term(s) Cattle ; Animals ; Child, Preschool ; Female ; Humans ; Arthritis, Juvenile/diagnosis ; Arthritis, Juvenile/epidemiology ; Lupus Erythematosus, Systemic ; Surveys and Questionnaires ; Habits ; Ecosystem
    Language English
    Publishing date 2022-08-30
    Publishing country England
    Document type Journal Article
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/1756-185X.14431
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Non-Rheumatic Chronic Comorbidities in Children with Juvenile Idiopathic Arthritis.

    Haşlak, Fatih / Guliyeva, Vafa / Hotaman, Büşra / Duman, Çisem / Yıldız, Mehmet / Günalp, Aybüke / Aslan, Esma / Kılıç Könte, Elif / Aliyeva, Ayten / Adrovic, Amra / Şahin, Sezgin / Barut, Kenan / Kasapçopur, Özgür

    Turkish archives of pediatrics

    2023  Volume 58, Issue 2, Page(s) 212–219

    Abstract: Objective: Juvenile idiopathic arthritis is a heterogeneous group of disorders and is the most common rheumatic condition in childhood. There are scarce data regarding all comorbidities in juvenile idiopathic arthritis patients.: Materials and methods! ...

    Abstract Objective: Juvenile idiopathic arthritis is a heterogeneous group of disorders and is the most common rheumatic condition in childhood. There are scarce data regarding all comorbidities in juvenile idiopathic arthritis patients.
    Materials and methods: We aimed to identify the non-rheumatic comorbidities in our juvenile idiopathic arthritis patients. Data were obtained cross-sectionally from the medical records and the face-to-face interviews for 6 consecutive months. Those with more than 1 rheumatic disease were excluded, and conditions that were highly related to the disease, such as uveitis, were not taken into account.
    Results: The study included 459 patients with female dominance (62.1%, n = 285). The median age of the patients was 12.87 (1.53-20.95) years. One hundred fifty patients (32.7%) had at least 1 comorbidity (5 patients had 3 comorbidities, and 24 patients had 2 comorbidities). The most common 3 non-rheumatic accompanying medical conditions in our patients were allergic rhinitis (n = 37, 8.1%), attention-deficit hyperactivity disorder (n = 35, 7.6%), and atopic dermatitis (n = 28, 6.1%). None of our patients with systemic JIA had any autoimmune disease. All the patients with primary immune deficiencies had anti-nuclear antibody positivity.
    Conclusion: Almost one-third of our patients had at least one comorbidity. This finding might be very helpful to us in planning our multi-disciplinary approach to our patients.
    Language English
    Publishing date 2023-03-01
    Publishing country Turkey
    Document type Journal Article
    ISSN 2757-6256
    ISSN 2757-6256
    DOI 10.5152/TurkArchPediatr.2023.22303
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Anti-nuclear antibody testing in children: How much is really necessary?

    Haslak, Fatih / Yildiz, Mehmet / Altun, Ilayda / Yilmaz, Gizem / Adrovic, Amra / Sahin, Sezgin / Koker, Oya / Aliyeva, Ayten / Barut, Kenan / Kasapcopur, Ozgur

    Pediatrics international : official journal of the Japan Pediatric Society

    2021  Volume 63, Issue 9, Page(s) 1020–1025

    Abstract: Background: Anti-nuclear antibody (ANA) testing is most commonly ordered by general pediatricians to evaluate children with musculoskeletal system complaints. Given the limited utility of the test, we aimed to estimate the effectiveness of ordering ANA ... ...

    Abstract Background: Anti-nuclear antibody (ANA) testing is most commonly ordered by general pediatricians to evaluate children with musculoskeletal system complaints. Given the limited utility of the test, we aimed to estimate the effectiveness of ordering ANA testing in childhood.
    Methods: Children referred to our department to be examined due to positive ANA findings between 2008 and 2020 were included in the study. Those with less than one-year follow-up period, those with previously known rheumatic or autoimmune disease, and those diagnosed as an autoimmune and/or rheumatic disease at the first visit were excluded. Data were obtained from their medical records, retrospectively. The parents of all of the patients were called via phone, data were verified, and missing information was collected.
    Results: Three hundred and fifty-eight patients (230 females) were eligible for the study. The median age of positive ANA findings was 9.31 (1.3-17.86) years and the median follow-up duration was 4.85 (1-11.91) years. Most of the patients had no underlying disease (n = 337, 94.1%). The most common reason for ordering ANA testing was to evaluate musculoskeletal system symptoms (n = 225, 62.8%). None of our patients referred to us due to positive ANA findings developed any autoimmune conditions or ANA associated rheumatic disease. Hypermobility syndrome is the most common final diagnosis among our ANA-positive patients.
    Conclusion: We suggest that instead of using it as a screening tool, ANA testing should be performed only if there is a strong suspicion of autoimmune diseases or certain rheumatic conditions, such as systemic lupus erythematosus.
    MeSH term(s) Adolescent ; Antibodies, Antinuclear ; Autoimmune Diseases/diagnosis ; Child ; Female ; Humans ; Lupus Erythematosus, Systemic ; Retrospective Studies ; Rheumatic Diseases/diagnosis
    Chemical Substances Antibodies, Antinuclear
    Language English
    Publishing date 2021-07-14
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 1470376-2
    ISSN 1442-200X ; 1328-8067
    ISSN (online) 1442-200X
    ISSN 1328-8067
    DOI 10.1111/ped.14592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children.

    Haslak, Fatih / Ozbey, Dogukan / Yildiz, Mehmet / Adrovic, Amra / Sahin, Sezgin / Koker, Oya / Aliyeva, Ayten / Guliyeva, Vafa / Yalcin, Gamze / Inanli, Gulmelek / Kocazeybek, Bekir S / Kasapcopur, Ozgur / Barut, Kenan

    Clinical rheumatology

    2022  Volume 41, Issue 5, Page(s) 1523–1533

    Abstract: Objective: We aimed to find out the asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among pediatric patients with rheumatic diseases and healthy children and to compare them with each other.: Methods: Patients ...

    Abstract Objective: We aimed to find out the asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among pediatric patients with rheumatic diseases and healthy children and to compare them with each other.
    Methods: Patients with familial Mediterranean fever (FMF), juvenile idiopathic arthritis (JIA), and juvenile systemic lupus erythematosus (jSLE) and healthy children as healthy control (HC) group who remained asymptomatic during the pandemic are examined by ELISA immunoglobulin (Ig) A and IgG tests in this cross-sectional study.
    Results: Overall, 149 subjects (90 females) were included in the study. While IgA was positive in 15 subjects (10%) (HC: 8, jSLE: 3, FMF: 2, JIA: 2; p = 0.196), IgG was positive in 14 subjects (9.4%) (HC: 7, JIA: 5, FMF: 1, jSLE: 1; p = 0.156). Nineteen subjects (12.75%) were IgA or IgG positive (HC: 8, JIA: 5, jSLE: 3, FMF: 3; p = 0.644). Although not significant, seropositivity was more often in HC group. Both IgA and IgG positivity were not found to be related to age, sex, underlying rheumatic diseases, and received treatments of the patients.
    Conclusion: We revealed that patients with childhood-onset rheumatic diseases, even if they receive immunosuppressive medication such as biologic or conventional disease-modifying anti-rheumatic drugs, might have an asymptomatic SARS-CoV-2 infection, similarly to their healthy peers. Key points • Although it has been already known that children are most likely to have asymptomatic SARS-CoV-2 infection, there is a lack of data on the disease course of children with rheumatic disease. • There was no significant difference regarding the asymptomatic SARS-CoV-2 seropositivity rates between healthy children and the patients with childhood-onset rheumatic diseases. • Patients with childhood-onset rheumatic diseases, even if they receive immunosuppressive medication, might have asymptomatic SARS-CoV-2 infection, similarly to their healthy peers.
    MeSH term(s) Arthritis, Juvenile/drug therapy ; COVID-19 ; Child ; Cross-Sectional Studies ; Female ; Humans ; Immunoglobulin A ; Immunoglobulin G ; Lupus Erythematosus, Systemic ; Male ; Rheumatic Diseases/epidemiology ; SARS-CoV-2 ; Seroepidemiologic Studies
    Chemical Substances Immunoglobulin A ; Immunoglobulin G
    Language English
    Publishing date 2022-01-19
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-022-06067-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study.

    Adrovic, Amra / Yildiz, Mehmet / Haslak, Fatih / Koker, Oya / Aliyeva, Ayten / Sahin, Sezgin / Barut, Kenan / Kasapcopur, Ozgur

    Rheumatology international

    2020  Volume 41, Issue 1, Page(s) 121–128

    Abstract: To evaluate the efficacy and safety of anti-interleukin (IL)-6 receptor antibody tocilizumab (TCZ) as a treatment option of juvenile systemic sclerosis (JSS). Nine JSS patients were assigned to a TCZ, additionally to conventional treatment (steroids, ... ...

    Abstract To evaluate the efficacy and safety of anti-interleukin (IL)-6 receptor antibody tocilizumab (TCZ) as a treatment option of juvenile systemic sclerosis (JSS). Nine JSS patients were assigned to a TCZ, additionally to conventional treatment (steroids, methotrexate, mycophenolate-mofetil). The modified Rodnan skin score (mRSS), carbon-monoxide diffusion capacity (DLCO), thorax high-resolution tomography (HRCT), patient global assessment (PGA) and Juvenile Systemic Sclerosis Severity (J4S) score were used to explore the efficacy of treatment. Nine JSS patients were treated with TCZ with a median treatment duration of 10 (1-21) months. Nine patients (77.8%) had radiologically confirmed improvement on thorax HRCT, 7 (77.8%) had decreased PGA (mean pre-treatment PGA 3.7 vs. 2.3 post-treatment PGA 2), 6 (66.7%) had increased DLCO (mean pre-treatment DLCO 69.14% vs. post-treatment DLCO 79.50%) after the TCZ treatment. In all patients mRSS and the J4S decreased: 26.1 vs. 19.7 and 8.2 vs. 4.7, respectively. Changes in mRSS, DLCO, PGA and J4S were statistically significant: p = 0.012, 0.04, 0.026 and 0.007, respectively. All patients tolerated well TCZ treatment. JSS is a rare condition characterized with skin fibrosis and internal organ involvement. Tocilizumab represents a potential treatment option for patients unresponsive to conventional treatment. Long-term prospective studies with higher number of patients are needed to provide more relevant data.
    MeSH term(s) Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Child ; Female ; Humans ; Interleukin-6/antagonists & inhibitors ; Male ; Pilot Projects ; Retrospective Studies ; Scleroderma, Systemic/drug therapy ; Thorax/drug effects ; Treatment Outcome ; Young Adult
    Chemical Substances Antibodies, Monoclonal, Humanized ; Interleukin-6 ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2020-10-27
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 8286-7
    ISSN 1437-160X ; 0172-8172
    ISSN (online) 1437-160X
    ISSN 0172-8172
    DOI 10.1007/s00296-020-04732-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic.

    Haslak, Fatih / Yildiz, Mehmet / Adrovic, Amra / Sahin, Sezgin / Koker, Oya / Aliyeva, Ayten / Barut, Kenan / Kasapcopur, Ozgur

    Rheumatology international

    2020  Volume 40, Issue 9, Page(s) 1423–1431

    Abstract: Concerns regarding the comorbidity as a significant risk factor for Coronavirus Disease-2019 (COVID-19), gave rise to an urgent need for studies evaluating patients with chronic conditions such as autoinflammatory diseases (AIDs). We prepared a web-based ...

    Abstract Concerns regarding the comorbidity as a significant risk factor for Coronavirus Disease-2019 (COVID-19), gave rise to an urgent need for studies evaluating patients with chronic conditions such as autoinflammatory diseases (AIDs). We prepared a web-based survey investigating the clinical findings and contact histories among pediatric patients with AIDs. Confirmed COVID-19 cases, patients with contact history and those with symptoms which were highly suggestive of COVID-19 were called via phone or recruited to a video or face to face appointment. Data of AIDs were obtained from their medical records, retrospectively. Laboratory and screening findings were confirmed by our national health registry website. There were 404 patients (217 female) eligible for the enrollment. During pandemic, 375 (93%) were on colchicine treatment and 48 (11.8%) were receiving biologic treatment. Twenty-four out of 404 patients were admitted to hospital due to COVID-19 suspicion. Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) was identified through rhinopharyngeal swabs in seven patients, six of whom were only on colchicine treatment. Only one patient with no finding of any severe respiratory complications was hospitalized. All of seven patients recovered completely. Among patients on biologic drugs, neither a symptom nor a positive polymerase chain reaction test for COVID 19 was detected. In conclusion, pediatric patients with AIDs, those receiving biologic treatment and/or colchicine, may not be at increased risk for neither being infected nor the severe disease course.
    MeSH term(s) Adalimumab/therapeutic use ; Adolescent ; Antibodies, Monoclonal, Humanized/therapeutic use ; Betacoronavirus ; Biological Products ; COVID-19 ; Child ; Child, Preschool ; Cohort Studies ; Colchicine/therapeutic use ; Coronavirus Infections/complications ; Coronavirus Infections/physiopathology ; Coronavirus Infections/therapy ; Cryopyrin-Associated Periodic Syndromes/complications ; Cryopyrin-Associated Periodic Syndromes/drug therapy ; Etanercept/therapeutic use ; Familial Mediterranean Fever/complications ; Familial Mediterranean Fever/drug therapy ; Female ; Hereditary Autoinflammatory Diseases/complications ; Hereditary Autoinflammatory Diseases/drug therapy ; Humans ; Infant ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Male ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/physiopathology ; Pneumonia, Viral/therapy ; SARS-CoV-2 ; Tubulin Modulators/therapeutic use ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Turkey ; Young Adult
    Chemical Substances Antibodies, Monoclonal, Humanized ; Biological Products ; Interleukin 1 Receptor Antagonist Protein ; Tubulin Modulators ; Tumor Necrosis Factor Inhibitors ; canakinumab (37CQ2C7X93) ; Adalimumab (FYS6T7F842) ; tocilizumab (I031V2H011) ; Etanercept (OP401G7OJC) ; Colchicine (SML2Y3J35T)
    Keywords covid19
    Language English
    Publishing date 2020-07-13
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 8286-7
    ISSN 1437-160X ; 0172-8172
    ISSN (online) 1437-160X
    ISSN 0172-8172
    DOI 10.1007/s00296-020-04645-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic

    Haslak, Fatih / Yildiz, Mehmet / Adrovic, Amra / Sahin, Sezgin / Koker, Oya / Aliyeva, Ayten / Barut, Kenan / Kasapcopur, Ozgur

    Rheumatol Int

    Abstract: Concerns regarding the comorbidity as a significant risk factor for Coronavirus Disease-2019 (COVID-19), gave rise to an urgent need for studies evaluating patients with chronic conditions such as autoinflammatory diseases (AIDs). We prepared a web-based ...

    Abstract Concerns regarding the comorbidity as a significant risk factor for Coronavirus Disease-2019 (COVID-19), gave rise to an urgent need for studies evaluating patients with chronic conditions such as autoinflammatory diseases (AIDs). We prepared a web-based survey investigating the clinical findings and contact histories among pediatric patients with AIDs. Confirmed COVID-19 cases, patients with contact history and those with symptoms which were highly suggestive of COVID-19 were called via phone or recruited to a video or face to face appointment. Data of AIDs were obtained from their medical records, retrospectively. Laboratory and screening findings were confirmed by our national health registry website. There were 404 patients (217 female) eligible for the enrollment. During pandemic, 375 (93%) were on colchicine treatment and 48 (11.8%) were receiving biologic treatment. Twenty-four out of 404 patients were admitted to hospital due to COVID-19 suspicion. Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) was identified through rhinopharyngeal swabs in seven patients, six of whom were only on colchicine treatment. Only one patient with no finding of any severe respiratory complications was hospitalized. All of seven patients recovered completely. Among patients on biologic drugs, neither a symptom nor a positive polymerase chain reaction test for COVID 19 was detected. In conclusion, pediatric patients with AIDs, those receiving biologic treatment and/or colchicine, may not be at increased risk for neither being infected nor the severe disease course.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #641082
    Database COVID19

    Kategorien

  9. Article ; Online: Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic

    Haslak, Fatih / Yildiz, Mehmet / Adrovic, Amra / Sahin, Sezgin / Koker, Oya / Aliyeva, Ayten / Barut, Kenan / Kasapcopur, Ozgur

    Rheumatology International

    2020  Volume 40, Issue 9, Page(s) 1423–1431

    Keywords Immunology ; Immunology and Allergy ; Rheumatology ; covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    ZDB-ID 8286-7
    ISSN 1437-160X ; 0172-8172
    ISSN (online) 1437-160X
    ISSN 0172-8172
    DOI 10.1007/s00296-020-04645-x
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Clinical features and outcomes of 76 patients with COVID-19-related multi-system inflammatory syndrome in children.

    Haslak, Fatih / Barut, Kenan / Durak, Cansu / Aliyeva, Ayten / Yildiz, Mehmet / Guliyeva, Vafa / Varol, Sevki Erdem / Cebeci, Sinem Oral / Aygun, Fatih / Varli, Yusuf Ziya / Ozel, Abdulrahman / Onan, Sertac Hanedan / Kocoglu, Ulkem / Erol, Meltem / Karagozlu, Fatih / Ulug, Nujin / Dedeoglu, Reyhan / Sahin, Sezgin / Adrovic, Amra /
    Oztunc, Funda / Kasapcopur, Ozgur

    Clinical rheumatology

    2021  Volume 40, Issue 10, Page(s) 4167–4178

    Abstract: Objectives: Multi-system inflammatory syndrome in children (MIS-C) is a less understood and a rare complication of coronavirus disease-2019 (COVID-19). Given the scarce data regarding this novel disease, we aimed to describe the clinical features and ... ...

    Abstract Objectives: Multi-system inflammatory syndrome in children (MIS-C) is a less understood and a rare complication of coronavirus disease-2019 (COVID-19). Given the scarce data regarding this novel disease, we aimed to describe the clinical features and outcomes of our patients with MIS-C and to evaluate the associated factors for the pediatric intensive care unit (PICU) admission.
    Methods: The MIS-C patients under 18 years old diagnosed and treated in three referral centers between July 2020 and March 2021 were included. Data of the patients were retrospectively obtained from their medical records.
    Results: Overall, 76 subjects (24 females) with a mean age of 8.17 ± 4.42 years were enrolled. Twenty-seven (35.5%) patients were admitted to the PICUs. The two most common systemic involvement patterns were cardiac and gastrointestinal. There was only one lethal outcome in a patient with underlying acute lymphoblastic leukemia. Those with higher procalcitonin levels at admission were found to stay longer in the hospital (r = 0.254, p = 0.027). The risk of PICU admission increased with age (aOR: 1.277; 95% CI: 1.089-1.498; p = 0.003) and with decreased initial serum albumin levels (aOR: 0.105; 95% CI: 0.029-0.378; p = 0.001).
    Conclusion: Although there is a wide clinical variability among the patients with MIS-C, we suggest that those with older age and lower initial serum albumin levels merit close monitoring due to their higher risk for PICU admission. Key Points • Although there is a wide variability regarding the management process among clinicians, MIS-C is a rare, severe, less understood complication of COVID-19 that may cause rapid clinical deterioration in the patients. • Clinicians should be aware of this condition in children with persistent fever and a family history of COVID-19. • Older age and low serum albumin levels are the independent predictors for the pediatric intensive care unit admission among MIS-C patients.
    MeSH term(s) Adolescent ; Aged ; COVID-19 ; Child ; Child, Preschool ; Female ; Hospitalization ; Humans ; Retrospective Studies ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome
    Language English
    Publishing date 2021-06-05
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-021-05780-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top